Sign in or create an account to add this stock to your watchlist.
About Genocea Biosciences (NASDAQ:GNCA)
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design immunotherapies and vaccines that act through T cell immune responses. Its lead product candidate is GEN-003, an investigational immunotherapy that is in Phase III trial for the treatment of genital herpes infections. The company is also develops GEN-009, which is in pre-clinical stage to treat neoantigen cancer; GEN-010 that is in pre-clinical stage for the treatment of patients in second generation neoantigen cancer; GEN-007, which is in research stage to Epstein-Barr virus; and GEN-006 that is in research stage for the treatment of immune-oncology-tumor-associated antigen cancer. It license agreement with University of California and Harvard University; and collaboration agreement with Novavax, Inc. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNCA
CUSIPN/A
Phone617-876-8191
Debt
Debt-to-Equity Ratio1.00
Current Ratio8.06
Quick Ratio8.06
Price-To-Earnings
Trailing P/E Ratio-0.47
Forward P/E Ratio-1.56
P/E GrowthN/A
Sales & Book Value
Annual Sales$230,000.00
Price / Sales351.25
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book5.83
Profitability
EPS (Most Recent Fiscal Year)($1.98)
Net Income$-56,710,000.00
Net MarginsN/A
Return on Equity-698.17%
Return on Assets-148.19%
Miscellaneous
Employees52
Outstanding Shares86,580,000
Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences (NASDAQ:GNCA) issued its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.14) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.14). View Genocea Biosciences' Earnings History.
When is Genocea Biosciences' next earnings date?
What price target have analysts set for GNCA?
7 equities research analysts have issued 1-year target prices for Genocea Biosciences' stock. Their forecasts range from $2.50 to $10.00. On average, they anticipate Genocea Biosciences' stock price to reach $4.7857 in the next twelve months. View Analyst Ratings for Genocea Biosciences.
What are Wall Street analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (4/18/2018)
- 2. Cantor Fitzgerald analysts commented, "GNCA shares could experience some weakness on the news of the departure of the CFO, Jonathan Poole, who resigned effective 3/23, to pursue other opportunities." (3/11/2018)
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include NantKwest (NK), Cellular Biomedicine Group (CBMG), Osiris Therapeutics (OSIR), ADMA Biologics (ADMA), Arsanis (ASNS), Organovo (ONVO), Fennec Pharmaceuticals (FENC), Compugen (CGEN), Pluristem Therapeutics (PSTI), Eiger Biopharmaceuticals (EIGR), Cidara Therapeutics (CDTX), Aptose Biosciences (APTO), Krystal Biotech (KRYS), Aevi Genomic Medicine (GNMX) and Brainstorm Cell Therapeutics (BCLI).
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 49)
- Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 73)
- Dr. Darren Higgins Ph.D., Scientific Co-Founder and Member of Scientific Advisory Board
- Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 46)
- Mr. Eric S. Hoffman, Chief Bus. Officer (Age 48)
Has Genocea Biosciences been receiving favorable news coverage?
News stories about GNCA stock have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Genocea Biosciences earned a coverage optimism score of 0.13 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 43.79 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Genocea Biosciences' major shareholders?
Genocea Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include NEA Management Company LLC (30.45%), BVF Inc. IL (6.09%), BlackRock Inc. (4.82%), Northern Trust Corp (0.97%), GSA Capital Partners LLP (0.29%) and Birchview Capital LP (0.23%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jonathan Poole and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.
Which institutional investors are buying Genocea Biosciences stock?
GNCA stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, BVF Inc. IL, BlackRock Inc., Northern Trust Corp, GSA Capital Partners LLP, Schwab Charles Investment Management Inc., Birchview Capital LP and California State Teachers Retirement System. Company insiders that have bought Genocea Biosciences stock in the last two years include Eric S Hoffman, Jonathan Poole and William D Clark. View Insider Buying and Selling for Genocea Biosciences.
How do I buy shares of Genocea Biosciences?
Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of GNCA stock can currently be purchased for approximately $0.9331.
How big of a company is Genocea Biosciences?
Genocea Biosciences has a market capitalization of $80.79 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-56,710,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Genocea Biosciences employs 52 workers across the globe.
How can I contact Genocea Biosciences?
Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]
MarketBeat Community Rating for Genocea Biosciences (GNCA)
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Genocea Biosciences (NASDAQ:GNCA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Genocea Biosciences in the last 12 months. Their average twelve-month price target is $4.7857, suggesting that the stock has a possible upside of 412.88%. The high price target for GNCA is $10.00 and the low price target for GNCA is $2.50. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.86 | 2.80 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.7857 | $4.7857 | $4.70 | $7.3750 |
| Price Target Upside: | 412.88% upside | 285.94% upside | 405.38% upside | 535.78% upside |
Genocea Biosciences (NASDAQ:GNCA) Consensus Price Target History
Genocea Biosciences (NASDAQ:GNCA) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Genocea Biosciences (NASDAQ:GNCA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Genocea Biosciences (NASDAQ GNCA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.95%
Institutional Ownership Percentage: 65.29%
Genocea Biosciences (NASDAQ GNCA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/17/2018 | William D Clark | CEO | Buy | 25,000 | $0.80 | $20,000.00 | 82,931 |  |
| 7/24/2017 | Jonathan Poole | CFO | Sell | 45,000 | $6.00 | $270,000.00 | 84,247 | |
| 11/8/2016 | Eric S. Hoffman | Insider | Buy | 7,000 | $3.49 | $24,430.00 | | |
| 11/7/2016 | Jonathan Poole | CFO | Buy | 7,000 | $3.34 | $23,380.00 | | |
| 11/7/2016 | William D. Clark | Insider | Buy | 2,800 | $3.49 | $9,772.00 | | |
| 5/9/2016 | Jonathan Poole | CFO | Buy | 4,000 | $3.88 | $15,520.00 | 8,213 | |
| 12/16/2015 | William D Clark | CEO | Buy | 3,800 | $6.45 | $24,510.00 | 43,607 | |
| 9/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $11.35 | $25,299.15 | 1,881 | |
| 6/19/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 30,004 | $13.04 | $391,252.16 | | |
| 6/17/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 10,618 | $13.01 | $138,140.18 | | |
| 6/16/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 46,000 | $13.24 | $609,040.00 | | |
| 6/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $10.52 | $23,449.08 | | |
| 5/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $10.21 | $22,758.09 | | |
| 4/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,283 | $11.77 | $26,870.91 | | |
| 3/17/2015 | Stephen J Hoffman | Director | Buy | 700,000 | $8.25 | $5,775,000.00 | | |
| 2/2/2015 | Jessica Baker Flechtner | VP | Sell | 4,699 | $8.50 | $39,941.50 | | |
| 9/12/2014 | Jessica Baker Flechtner | VP | Sell | 6,435 | $12.00 | $77,220.00 | | |
| 9/11/2014 | Paul Giannasca | VP | Sell | 4,071 | $11.84 | $48,200.64 | | |
| 9/10/2014 | Paul Giannasca | VP | Sell | 834 | $12.35 | $10,299.90 | | |
| 9/9/2014 | Paul Giannasca | VP | Sell | 2,455 | $12.43 | $30,515.65 | | |
| 9/8/2014 | Paul Giannasca | VP | Sell | 2,970 | $12.80 | $38,016.00 | | |
| 8/29/2014 | Paul Giannasca | VP | Sell | 6,760 | $12.50 | $84,500.00 | | |
| 8/14/2014 | Polaris Venture Management Co. | Major Shareholder | Sell | 9,660 | $13.01 | $125,676.60 | | |
| 8/12/2014 | Polaris Venture Management Co. | Major Shareholder | Sell | 63,794 | $13.28 | $847,184.32 | | |
| 2/10/2014 | Plc Glaxosmithkline | Insider | Buy | 143,773 | $12.00 | $1,725,276.00 | | |
| 2/10/2014 | Polaris Venture Management Co. | Major Shareholder | Buy | 232,820 | $12.00 | $2,793,840.00 | | |
| 2/10/2014 | Stephen J Hoffman | Director | Buy | 250,931 | $12.00 | $3,011,172.00 | | |
(Data available from 1/1/2013 forward)
Genocea Biosciences (NASDAQ GNCA) News Headlines
| Source: |
|
Genocea Biosciences (NASDAQ:GNCA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Genocea Biosciences (NASDAQ:GNCA) Income Statement, Balance Sheet and Cash Flow Statement
Genocea Biosciences (NASDAQ GNCA) Stock Chart for Sunday, May, 27, 2018
Loading chart…
